Large population-based study suggests no increased major malformation risk following maternal first trimester atomoxetine use

A collaborative of researchers from Nordic countries and the US have published a population-based comparative cohort study including approximately 2.4 million pregnancies ending in live births in Denmark, Iceland, Norway, and Sweden (2003-2017) and approximately 1.8 million in the US, investigating the risk of major malformation following maternal first trimester atomoxetine use. More information can be found here. Photo by […]

» Read more

Maternal and perinatal outcomes following pre-Delta, Delta, and Omicron SARS-CoV-2 variants infection among unvaccinated pregnant women

Researchers affiliated with the French and Swiss Covi-Preg registry, led by ENTIS members from the Swiss Teratology Information Service, have published a prospective cohort study describing the maternal and perinatal outcomes among unvaccinated pregnant women that tested positive for SARS-CoV-2 during the pre-Delta, Delta, and Omicron periods. More information can be found here.

» Read more

No increased risk of ADHD following benzodiazepine/z-drug hypnotic use in pregnancy

Researchers affiliated to the PharmacoEpidemiology and Drug Safety Research Group at the University of Oslo, led by ENTIS member Professor Hedvig Nordeng, have published a large comparative cohort study investigating childhood ADHD risks following maternal benzodiazepine/z-drug hypnotic use in pregnancy. The full study sample consisted of more than 82,000 singleton pregnancies, with 681 offspring exposed to benzodiazepines or z-drug hypnotics […]

» Read more

Reassuring evidence from a large population-based study of antipsychotic use and malformation risks

A collaboration of researchers from the US and Nordic countries have published a very large population-based cohort study including more than 6.5 million pregnancies. The study investigated malformation risks following antipsychotic use and generally provides some very reassuring data. More information can be found here. Photo by Christina Victoria Craft on Unsplash

» Read more

A study of fetal and maternal outcomes comparing buprenorphine and methadone exposure in pregnancy

US researchers have published a study investigating both maternal and fetal outcomes among women using buprenorphine or methadone for opioid use disorder in pregnancy. The results indicate a lower risk of adverse neonatal outcomes for buprenorphine exposed pregnancies while the risk of adverse maternal outcomes was similar among those using buprenorphine and methadone. More information can be found here. Photo […]

» Read more

A critical appraisal of the malformation risks following pregabalin use in early pregnancy

ENTIS affiliated researchers from the UK, Denmark and Israel have published a literature review and critical appraisal which explores whether recent SmPC updates applied to some pregabalin products are justified, and provides clarity on the risk-benefit balance for pregabalin use in early pregnancy. This publication was developed after the ENTIS Board and Scientific Committee submitted an official communication to the EMA […]

» Read more

Use of calcium-based antacids and PPIs during pregnancy not found to reduce the risk of late-onset preeclampsia

A collaborative of researchers from Radboud University Medical Center, the Netherlands Pharmacovigilance Centre Lareb and Maastricht University, led by ENTIS associate member Dr Marleen van Gelder, have published a prospective comparative cohort study investigating preeclampsia risk among women exposed to calcium-based antacids and PPIs during pregnancy. More information can be found here. Photo by Mufid Majnun on Unsplash

» Read more
1 2 3 4 18